News

Press Releases

Nov 06, 2008
Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
Nov 06, 2008
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Nov 03, 2008
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
Oct 30, 2008
Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
Sep 17, 2008
Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
Sep 16, 2008
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model Study Published in the Proceedings of the National Academy of Sciences
Sep 04, 2008
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Aug 07, 2008
Repligen Reports First Quarter Fiscal Year 2009 Financial Results
Jul 31, 2008
Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results Thursday, August 7th, 11:00 a.m. EDT
Jul 08, 2008
Repligen First in North America to Receive Certification for Business Continuity
Jul 01, 2008
Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
Jun 30, 2008
Repligen Added to Russell 3000 Index
Jun 18, 2008
Repligen Announces Share Repurchase Program
Jun 12, 2008
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder; Reports Full Assessment of Data from Positive Phase 2a Trial
Jun 12, 2008
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Jun 06, 2008
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results Thursday, June 12th, 11:00 a.m. EDT
Apr 16, 2008
Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
Apr 08, 2008
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia® Lawsuit
Apr 07, 2008
Repligen Announces Conference Call to Update Orencia® Lawsuit Tuesday, April 8th, 9:00 a.m. EST
Mar 26, 2008
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging